VJHemOnc is committed to improving our service to you

SOHO 2020 | Incidence of GvHD in myeloma treated with daratumumab after allo-HCT

VJHemOnc is committed to improving our service to you

Joshua Richter

Joshua Richter, MD, of Mount Sinai Medical Center, New York, NY, discusses the incidence of graft-versus-host disease in patients with multiple myeloma treated with daratumumab, a CD38 monoclonal antibody, after allogeneic hematopoietic cell transplantation (allo-HCT). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter